← Back to patent-cliff list

Rilzabrutinib

Tier C — Watch / trade

Rilzabrutinib

Principia Biopharma Inc
Originator
2025
First approval
-
Expiry (public)
$0.01B ▲
Peak sales
Small molecule
Type

Targets:BTK

Brand:Wayrilz

Indications (approved):Immune thrombocytopenic purpura

Regional status

US
Approved
2025-08-29
EU
Approved
2025-12-22
China
Approved
2026-09-02
Japan
Approved
2026-06-23

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 9 · Total yield 79mg (Rilzabrutinib)
Rilza-0012380-63-4Rilza-002151266-23-8Rilza-003143900-43-0Rilza-004461699-13-8Rilza-0051414356-30-1Rilza-0061414356-80-1Rilza-0071414356-82-3Rilza-0081414356-84-5Rilza-0091575591-71-7Rilza-010121219-03-2Rilza-01198-80-6Rilza-0121138557-58-0Rilza-01313206-46-7Rilza-0141254115-23-5API · Rilzabrutinib
CodeCAS No.Intermediate
Rilza-0012380-63-4Available1H-pyrazolo[3,4-d]pyrimidin-4-amine
Rilza-002151266-23-8Available3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Rilza-003143900-43-0Availabletert-butyl (R)-3-hydroxypiperidine-1-carboxylate
Rilza-004461699-13-8Availabletert-butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
Rilza-0051414356-30-1Available2-fluoro-4-phenoxyphenylboronic acid
Rilza-0061414356-80-1Availabletert-butyl 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
Rilza-0071414356-82-3Available3-(2-fluoro-4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Rilza-0081414356-84-5Available3-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-3-oxopropanenitrile
Rilza-0091575591-71-7Available2-methyl-2-(4-(oxetan-3-yl)piperazin-1-yl)propanal
Rilza-010121219-03-2Available4-bromo-3-fluorophenol
Rilza-01198-80-6Availablephenylboronic acid
Rilza-0121138557-58-0Available1-bromo-2-fluoro-4-phenoxybenzene
Rilza-01313206-46-7Available2-bromo-2-methylpropanal
Rilza-0141254115-23-5Available1-(oxetan-3-yl)piperazine

Frequently asked questions

What are the approved indications of Rilzabrutinib?

Approved indications include: Immune thrombocytopenic purpura.

When does the Rilzabrutinib patent expire?

No public expiry year is available for Rilzabrutinib yet; this page updates once verified.

How many synthesis routes are recorded for Rilzabrutinib?

1 synthesis routes are recorded; the shortest is 9 steps with 79mg (Rilzabrutinib) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Rilzabrutinib intermediates?

14 intermediate CAS of Rilzabrutinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Rilzabrutinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-22